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Purpose: Various studies searching for biomarkers to predict tumor metastasis or prognosis in both esophageal squamous 
cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) are currently underway. However, few data 
have been reported on its association with colorectal cancer (CRC). Single nucleotide polymorphisms (SNPs) are the most 
common known form of human genetic variation and may contribute to an increased susceptibility to cancer including CRC. 
The present study aimed to investigate whether the polymorphisms in the CTTN gene are associated with susceptibility to 
CRC in the Korean population. Methods: A case-control study was performed to examine the relationship between the CTTN 
g.-9101C＞T, g.-8748C＞T, and g.72C＞T polymorphisms and the risk of CRC. Polymerase chain reaction-restriction frag-
ment length polymorphism analysis of g.-8748C＞T, g.-9101C＞T and Taqman analysis of g.72C＞T were performed on 
blood samples from 218 patients with CRC and 533 control individuals. The g.-9101C＞T, g.-8748C＞T, and g.72C＞T SNPs 
in CTTN and their haplotypes were analyzed. Results: The genotype and allele frequencies of g.-9101C＞T, g.-8748C＞T, and 
g.72C＞T did not differ between the patient group and the control group. Further, the haplotype of CTTN g.-9101C＞T, 
g.-8748C＞T, and g.72C＞T did not differ between patient group and the control group. However, the genotype and allele 
frequencies of CTTN g.-9101C＞T were significantly increased in the lymph node positive CRC group compared to the con-
trol group. Conclusion: The CTTN g.-9101C＞T polymorphism may influence lymph node positive CRC.
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INTRODUCTION
Recent developments in genetics have revealed the en-
tire sequence of the human genome. As a result, many 
studies have shown associations between specific poly-
morphisms and disease [1]. In particular, colorectal cancer 
(CRC) appears to have a high frequency of diverse genetic 
polymorphisms that are contributing factors, including 
genetic tendencies and personal factors, etc., which usu-
ally converge. In addition, health screening colonoscopies 
are actively performed, which have shown that CRC is one 
of the 3 leading causes of cancer related death in men and 
women worldwide. Even among patients with CRC who 
undergo potentially curative resection, 40 to 50% ulti-CTTN polymorphisms with the risk of CRC
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mately relapse and die of metastatic disease.
Although tumor-nodes-metastasis (TNM) classification 
is useful for staging CRC in patients and selecting specific 
treatments for them, it is not sufficient; patients at the 
same stage have various outcomes, which suggests that 
conventional staging procedures cannot precisely predict 
cancer prognosis. Therefore, there is a great need to identi-
fy molecular markers of more aggressive colorectal tumor 
phenotypes to appropriately select patients for adjuvant 
systemic or targeted therapy. In the sixth edition of the 
American Joint Committee on Cancer (AJCC) cancer stag-
ing manual, nonanatomical factors were judiciously add-
ed to the classifications that modified stage groups. This 
shift away from purely anatomic information has been ex-
tended in the 7th edition of the AJCC cancer staging 
manual. Relevant markers are so important and are re-
quired by clinicians in order to make clear treatment deci-
sions that they have been included in the groupings. 
Example markers used in staging CRC include perineural 
invasion, microsatellite instability, pre-operative or pre- 
treatment carcinoembryonic antigen, K-Ras (V-Ki-ras2, 
Kirsten rat sarcoma viral oncogene) gene analysis, and 18q 
loss of heterozygosity assay, and many other biological 
markers associated with the prognosis of malignant tu-
mors have been studied [2,3].
Identification of the factors regulating carcinogenesis 
and the progression of CRC would contribute to reducing 
the occurrence of CRC, as well as improving the clinical 
outcome for the treatment of the disease. To better under-
stand the underlying mechanism of carcinogenesis in 
CRC, genome-wide association studies (GWAS) are being 
performed around the world. Efforts to detect the most 
important single nucleotide polymorphisms (SNPs) for 
disease are an area of intense study. In epidemiological 
studies, GWAS generally examine all or most of the genes 
of different individuals of a particular species to identify 
the extent to which the genes vary from individual to 
individual. The variations in genotypes are then asso-
ciated with specific diseases or malignancies. With regard 
to the biological significance of SNPs in the progression of 
CRC, several studies have been reported. In high-grade 
soft tissue sarcoma, patients with the Gly/Gly genotype of 
the FGFR4 SNP were found to have a better prognosis with 
regard to cumulative overall and metastasis free survival 
[4].
Cortactin is an actin-binding protein that activates the 
Arp2/3 complex, which regulates the actin cytoskeleton 
and inhibits debranching of dendritic actin networks [5]. 
Cortactin is overexpressed in many types of human can-
cers, including head and neck squamous cell carcinoma 
(HNSCC) and esophageal squamous cell carcinoma, col-
orectal, gastric, hepatocellular, breast, and ovarian cancers. 
Most frequently, cortactin overexpression occurs through 
chromosomal amplification of the 11q13 region; however, 
overexpression has also been reported in tumors in the ab-
sence of this amplification. Actin cytoskeleton remodeling 
has effects on cell migration, motility, and adhesion, as 
well as tumor invasion and metastasis [5,6]. In some stud-
ies, overexpression of cortactin was correlated with histo-
logical differentiation, T and N stage in gastric cancer, 
depth of invasion in CRC, and poor prognosis in patients 
with lymph node metastasis [7,8]. However, only few 
studies have examined the association of CTTN poly-
morphisms and haplotypes with CRC. For this reason, our 
study was aimed at investigating the association of the 
CTTN g.-9101C＞T, g.-8748C＞T, and g.72C＞T poly-
morphisms with the risk of CRC.
METHODS
For this case-control study, blood samples were col-
lected from 218 consecutive patients who were diagnosed 
with CRC at our hospital between June 2001 and August 
2007. As controls, we collected blood samples from 533 
healthy volunteers. The CTTN g.-9101C＞T, g.-8748C＞T, 
and g.72C＞T polymorphisms were analyzed in the 2 
groups retrospectively, and their association with CRC 
was assessed. TNM cancer staging criteria from the 7th ed-
ition of the AJCC manual were applied, and T1 and T2 
were placed in the Ta group, and T3 and T4 were placed in 
the Tb group, respectively. Regional lymph nodes were 
applied to the N0 in the N(－) group, and the N1 and N2 in 
the N(＋) group, respectively. The study protocol was ap-
proved by the Ethics Committee and written-informed 
consent was obtained from all participants.Seok Youn Lee, et al.
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Fig. 1. CTTN genotyping restriction fragment length polymor-
phism result. Restriction enzyme digestion of the polymerase chain 
reaction products for g.-9101C＞T (630 bp) and g.-8748C＞T (630 
bp) yielded 2 fragments of 490 bp and 140 bp.
Analysis of CTTN polymorphisms
Genomic DNA was extracted from the peripheral blood 
of individuals in the patient and control groups and the 
CTTN  gene g.-9101C＞T, g.-8748C＞T polymorphisms 
were analyzed using the polymerase chain reaction-re-
striction fragment length polymorphism (PCR-RFLP) 
method, and g.72C＞T was analyzed by the TaqMan 
method. In CRC patients, the haplotype of these CTTN 
SNPs was analyzed from peripheral blood collected be-
fore surgery.
PCR-RFLP
Portions of the CTTN gene containing either the 9101C＞
T or -8748C＞T polymorphic sites were partially amplified 
using a primer set for -9101C＞T and -8748C＞T 
(CTTN-PF1; TCCCAGGTGAGTACCCATGTGGT and 
CTTN-PR1; TCGCGGCCAGGCGACGCCACA). An ini-
tial PCR denaturation step was performed at 95
oC for 5 mi-
nutes, followed by 30 cycles of denaturation at 98
oC for 10 
seconds, annealing at the melting temperature of each pri-
mer pair for 15 seconds, and extension at 72
oC for 30 sec-
onds, with a final 10-minute extension at 72
oC. The PCR 
products for -9101C＞T and -8748C＞T were digested 
with 2 U of Eco 52 I for 12 hours at 37°C and with 1 U of Nar 
I for 12 hours at 37
oC, respectively, and then separated on 
a 1.5% agarose gel and visualized under UV with ethi-
dium bromide. Restriction enzyme digestion of the PCR 
products for -9101C＞T (630 bp) and -8748C＞T (630 bp) 
yielded 2 fragments of 490 bp and 140 bp (Fig. 1).
TaqMan analysis
The assay reagents for the g.72C＞T (rs2298397) poly-
morphism in the CTTN gene were designed by Applied 
Biosystems (Foster City, CA, USA). The reagents consisted 
of a 40× mix of unlabeled PCR primer and TaqMan MGB 
probes (FAM and VIC dye-labeled). A 10 μL reaction was 
optimized with 0.125 μL of 40× reagent, 5 μL of 2× TaqMan 
Genotyping Master mix (Applied Biosystems), and 2 μL 
containing 50 ng of genomic DNA. The PCR conditions 
were as follows: 1 cycle of 95
oC for 15 minutes, 50 cycles at 
95
oC for 10 seconds and 60
oC for 45 seconds. The PCR was 
performed in a Rotor-Gene thermal cycler RG6000 (Cor-
bett Life Science, Mortlake, Australia). The samples were 
read and analyzed using Rotor-Gene 1.7.40 software (Cor-
bett Life Science). The reference sequence for the CTTN 
gene was based on the sequence of human chromosome 
11, 11q13.
Statistical analysis
We determined whether the allelic distribution of the 
SNPs was in Hardy-Weinberg equilibrium using the 
chi-square test. The allele and genotype frequencies of 
these SNPs were compared between the patients and con-
trols using the chi-square test or Fisher’s exact test. We also 
tested the frequencies of these haplotypes based on the ex-
pectation maximization algorithm using SNPAlyze soft-
ware (Dynacom Co., Mobara, Japan). The association of 
the haplotype frequencies with CRC was evaluated by a 
permutation test. In all cases, a P-value of ＜0.05 was con-
sidered statistically significant.
RESULTS
Genotype and allele frequencies of the CTTN 
polymorphisms in CRC patients and the controls 
and the risk of CRC
The genotype frequencies of the CTTN g.-9101C＞T 
polymorphism were 97.0% (TT), 3.0% (TC), and 0% (CC) in 
the patient group, and 98.6% (TT), 1.4% (TC), and 0% (CC) 
in the control group. The genotype frequencies of the CTTN polymorphisms with the risk of CRC
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Table 1. G e n o t y p e  a n d  a l l e l e  f r e q u e n c i e s  o f  t h e  C T T N  p o l y -
morphisms between patients with colorectal cancer and the 
control group and the risk of colorectal cancer
Position
a) Genotype/
allele
Total P-value
b)
Control CRC vs. CRC
g.-9101C＞T
  (rs12576561)
TT 430 (98.6)   97 (97.0)
0.522 TC     6 (1.4)     3 (3.0)
CC     0 (0)     0 (0)
T 866 (99.3) 197 (98.5)
0.381
C     6 (0.7)     3 (1.5)
g.-8748C＞T
  (rs11825736)
TT 404 (94.2)   91 (97.9)
0.348 TC   25 (5.8)     2 (2.2)
CC     0 (0)     0 (0)
T 833 (97.1) 184 (98.9)
0.204
C   25 (2.9)     2 (1.1)
g.72C＞T
  (rs2298397)
CC 416 (78.1) 171 (78.4)
0.331 CT 107 (20.1)   46 (21.1)
TT   10 (1.9)     1 (0.5)
C 939 (88.1) 388 (89.0)
0.658
T 127 (11.9)   48 (11.0)
Values are presented as number (%).
CRC, colorectal cancer.
a)Calculated from the translation start site. 
b)P-values were 
determined by Fisher's exact test or chi-square test from a 2 × 3 
contingency table.
CTTN g.-8748C＞T polymorphism were 97.9% (TT), 2.0% 
(TC), and 0% (CC) in the patient group, and 94.2% (TT), 
5.8% (TC), and 0% (CC) in the control group. The genotype 
frequencies of the CTTN g.72C＞T polymorphism were 
78.4% (CC), 21.1% (CT), and 0.46% (TT) in the patient 
group, and 78.1% (CC), 20.1% (CT), and 1.9% (TT) in the 
control group. The genotype and allele frequencies of 
CTTN g.-9101C＞T, g.-8748C＞T, and g.72C＞T did not 
differ between the patient group and the control group 
(Table 1).
Genotype and allele frequencies of the CTTN poly-
morphisms according to the T and N stages of CRC 
and the controls and the risk of CRC
The genotype and allele frequencies of CTTN g.-9101C＞T, 
g.-8748C＞T, and g.72C＞T did not differ between the 2 
CRC groups according to T stage. However, the genotype 
and allele frequencies of CTTN g.-9101C＞T were sig-
nificantly higher in the lymph node-positive CRC group 
than in the control group (P = 0.036 and P = 0.039, re-
spectively) (Tables 2, 3).
Haplotype frequencies of the CTTN polymorphis-
ms between CRC patients and the controls and 
the risk of CRC
The major haplotype of CTTN g.-9101 C＞T, g.-8748C＞
T, and g. 72C＞T was T-T-C, T-T-T. The haplotype did not 
differ between CRC patients and the controls (Table 4).
Haplotype frequencies of the CTTN polymorphis-
ms according to T and N stages of CRC and the 
the controls and the risk of CRC
The haplotype frequencies of CTTN g.-9101C＞T, 
g.-8748C＞T, and g.72C＞T did not differ between CRC 
groups and the control groups (Tables 5, 6).
DISCUSSION
There has been an explosion of information concerning 
the natural genetic variation in the human genome and its 
functional and clinical significance. This scientific prog-
ress is beginning to allow us to disentangle the complex 
role that genetic factors play in the causation and pro-
gression of common multi-factorial diseases [1,2]. Recen-
tly, the incidence of CRC in Korea has been increasing 
sharply, and it currently ranks second among digestive or-
gan malignancies. This is thought to be related to the rapid 
changes in the lifestyle of Koreans over past few decades 
as a result of industrialization and high-calorie food and 
fat increased intake. Multi-factorial diseases such as can-
cer occur as a result of the interplay between a number of 
genetic and environmental factors. These genetic factors 
may differ from those in single gene disorders in that the 
effect of individual genes is small; in other words, the 
probability of a genetic change resulting in disease is low. 
Only in combination with numerous other genetic and en-
vironmental variables does a polymorphic gene predis-
pose to disease [9-11]. Depending on the frequency of nat-
urally occurring DNA sequences and their ability to cause 
disease, these variations are referred to as either poly-
morphisms (a frequency of  ＞1 %  i n  t h e  n o r m a l  p o p -
ulation) or mutations (a frequency of ＜1%, which usually 
results in disease). However, not all mutations result in 
disease, and some polymorphisms are functionally im-Seok Youn Lee, et al.
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Table 2. Genotype and allele frequencies of the CTTN polymorphisms among the Ta and Tb groups of colorectal cancer patients and the 
control group and the risk of colorectal cancer
Position
a) Genotype/
allele
T
b) P-value
c)
Control Ta Tb vs. Ta vs. Tb
  g.-9101C＞T (rs12576561) TT 430 (98.6) 23 (100)   74 (96.1)
0.852 0.300 TC     6 (1.4)  0 (0)    3 (3.9)
CC     0 (0)  0 (0)    0 (0)
T 866 (99.3) 46 (100) 151 (98.1)
0.266 0.140
C     6 (0.7)  0 (0)    3 (2.0)
  g.-8748C＞T (rs11825736) TT 404 (94.2) 20 (100)  71 (97.3)
0.541 0.557 TC   25 (5.8)  0 (0)    2 (2.7)
CC     0 (0)  0 (0)    0 (0)
T 833 (97.1) 40 (100) 144 (98.6)
0.622 0.410
C   25 (2.9)  0 (0)    2 (1.4)
  g.72C＞T (rs2298397) CC 416 (78.1) 47 (90.4) 124 (74.7)
0.101 0.250 CT 107 (20.1)  5 (9.6)  41 (24.7)
TT   10 (1.9)  0 (0)    1 (0.6)
C 939 (88.1) 99 (95.2) 289 (87.1)
0.033 0.631
T 127 (11.9)  5 (4.8)  43 (13.0)
Values are presented as number (%).
a)Calculated from the translation start site. 
b)Primary tumor stages were applied to the T1 and T2 in the Ta group and T3 and T4 in the Tb group.
c)P-values were determined by Fisher's exact test or chi-shared test from a 2 × 3 contingency table.
Table 3. Genotype and allele frequencies of the CTTN polymorphisms in the N (－) and N (＋) colorectal cancer groups and the control group 
and the risk of colorectal cancer
Position
a) Genotype or 
allele
Lymph node
b) P-value
c)
Control N (－)N  ( ＋)v s .  N  ( －)v s .  N  ( ＋)
  g.-9101C＞T (rs12576561) TT 430 (98.6)   56 (100)   40 (93.0)
0.677 0.036 TC     6 (1.4)    0 (0)    3 (7.0)
CC     0 (0)    0 (0)    0 (0)
T 866 (99.3) 112 (100)  83 (96.5)
0.517 0.039
C     6 (0.7)    0 (0)    3 (3.5)
  g.-8748C＞T (rs11825736) TT 404 (94.2)  51 (100)  39 (95.1)
0.208 0.970 TC   25 (5.8)    0 (0)    2 (4.9)
CC     0 (0)    0 (0)    0 (0)
T 833 (97.1) 102 (100)  80 (97.6)
0.099 1.000
C   25 (2.9)    0 (0)    2 (2.4)
  g.72C＞T (rs2298397) CC 416 (78.1)  93 (78.2)  77 (78.9)
0.304 0.835 CT 107 (20.1)  26 (21.9)  20 (20.4)
TT   10 (1.9)    0 (0)    1 (1.0)
C 939 (88.1) 212 (89.1) 174 (88.8)
0.739 0.904
T 127 (11.9)  26 (10.9)  22 (11.2)
Values are presented as number (%).
a)Calculated from the translation start site. 
b)Regional lymph nodes were applied to the N0 in the N (－) group and the N1 and N2 in the N
(＋) group. 
c)P-values were determined by Fisher's exact test or chi-square test from a 2 × 3 contingency table.
portant and have been implicated in disease pathogenesis. 
Polymorphisms exist in several forms, and changes in-
volving single nucleotides are referred to as SNPs. SNPs 
may occur at a frequency as high as 1 in every 185 base 
pairs, with up to 16 million polymorphisms in the human 
genome [12].
Cortactin was first identified as a major substrate for Src 
kinase. Because it localized to cortical actin structures, it CTTN polymorphisms with the risk of CRC
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Table 4. Haplotype frequencies of the CTTN polymorphisms 
between colorectal cancer patients and the controls and the risk of 
colorectal cancer
Haplotype Frequency
a) P-value
b)
g.-9101C＞T g.-8748C＞T g.72C＞TC o n t r o l C R Cv s .  C R C
T T C 0.866 0.877 0.764
TT T 0 . 0 9 7 0.093 0.824
Others 0.029 0.012 -
CRC, colorectal cancer.
a)Values were constructed using the expectation maximization 
algorithm with genotyped single nucleotide polymorphisms. 
b)P-values were determined by permutation test.
Table 5. Haplotype frequencies of the CTTN polymorphisms among the Ta and Tb groups of colorectal cancer patients and the control group 
and the the risk of colorectal cancer
Haplotype Frequency
a) P-value
b)
g.-9101C＞T g.-8748C＞Tg . 7 2 C ＞T Control Ta Tb vs. Ta vs. Tb
T T C 0.866 0.912 0.867 0.539 0.962
TT T 0 . 0 9 7 0.088 0.094 0.796 0.936
Others 0.029 0 0.016 - -
Primary tumor stages were applied to the T1 and T2 in the Ta group and T3 and T4 in the Tb group.
a)Values were constructed using the expectation maximization algorithm with genotyped single nucleotide polymorphisms. 
b)P-values were
determined by permutation test. 
Table 6. Haplotype frequencies of the CTTN polymorphisms among the N (－) and N (＋) groups of colorectal cancer patients and the control 
group and the risk of colorectal cancer
Haplotype Frequency
a) P-value
b)
g.-9101C＞T g.-8748C＞Tg . 7 2 C ＞TC o n t r o l N  ( －)N  ( ＋)v s .  N  ( －)v s .  N  ( ＋)
T T C 0.866 0.895 0.851 0.474 0.763
TT T 0 . 0 9 7 0.105 0.081 0.713 0.614
Others 0.029 0 0.027 --
Regional lymph nodes were applied to the N0 in the N (－) group and the N1 and N2 in the N (＋) group.
a)Values were constructed using the expectation maximization algorithm with genotyped single nucleotide polymorphisms. 
b)P-values were
determined by permutation test.
was named cortactin. At that time, little was known about 
its function, except that it bound to actin filaments, had an 
SH3 domain, and that its C-terminus was phosphorylated 
by Src kinase [13]. Subsequently, the cortactin gene was 
found to be identical to Ems1, a gene that is frequently 
overexpressed in breast and head and neck cancers due to 
its presence in the 11q13 amplicon. Amplification of 11q13 
has been frequently tied to poor prognosis, including 
higher pathological stage, lymph node and distant meta-
stasis, and decreased survival [14,15]. Although many oth-
er genes are present within this amplicon, the consistent 
overexpression of cortactin in 11q13 amplified tumors 
along with its ubiquitous presence in cell motility struc-
tures, such as lamellipodia and invadopodia, have gen-
erated a great deal of interest in the role of cortactin in tu-
mor invasion [13-15].
In HNSCC, 30 to 40% of tumors contain the 11q13 am-
plicon, and it clearly correlates with poor patient prog-
nosis, including decreased survival [16]. In addition, a 
number of interesting genes are present in this amplicon, 
including TPC2, ORAOV1/TAOS1, FGF4, CCND1, FGF19, 
FGF3, FLJ10261, FADD, PP1A1, TMEM1GA, and SHANK2 
[17]. Of these, cyclinD1 and EMS1/cortactin have been 
considered to be the best candidates for promoting tumor 
aggressiveness, since unlike many of the other genes in the 
amplicon, they are consistently overexpressed upon am-
plification [18]. Between these 2 genes, cortactin has been 
more highly correlated with poor prognosis in HNSCC 
and estrogen receptor-negative breast cancers, whereas 
cyclin D1 has been associated with poor prognosis in es-
trogen receptor-positive breast cancers [15,19].
Timpson et al. [20] reported that co-overexpression of Seok Youn Lee, et al.
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cyclin D1 and cortactin in HNSCC cells promotes resist-
ance to gefitinib, an epidermal growth factor receptor an-
tagonist drug, as defined by the IC50 for proliferation. 
Rothschild et al. [21] examined HNSCC cells with 11q13 
amplification, and found that generally cortactin plays an 
important role in migration and invasion and also pro-
motes resistance to gefitinib-induced inhibition of migra-
tion; however, it is unclear whether any of the other genes 
in the amplicon contribute to this phenotype.
A few studies have examined the function of cortactin in 
tumors grown in mice. In a spontaneous model of breast 
tumorigenesis, the expression of cortactin under the mouse 
mammary tumor virus promoter did not increase the 
number of new tumors, regardless of the presence or ab-
sence of cyclin D1 overexpression. Therefore, cortactin is 
unlikely to act as a tumor initiator [22]. This finding is not 
inconsistent with the known cortactin biology, since 11q13 
amplification usually occurs as a late change in cancer, and 
further, it suggests that cortactin expression may be im-
portant mainly in the promotion of tumor progression. 
How might cortactin promote tumour progression? The 
role of cortactin in regulating the formation of actin-based 
structures intimately associated with cell motility, its lo-
calization to podosome-like structures in transformed 
cells, and the enhancement of cell migration upon cortac-
tin overexpression are all consistent with a role in cancer 
cell invasion and metastasis [23-25].
In CRC, Hirakawa et al. [26] demonstrated that local-
ization of cortactin at the cell periphery was significantly 
associated with lymph node involvement with lymph 
node involvement. In addition, the results indicate that the 
association between ZO-1 and cortactin plays an im-
portant role in regulating cell adhesion and spreading. 
However, research studies on CTTN polymorphism are 
extremely rare. Based on the current study, the relation-
ship between CTTN polymorphism and CRC will provide 
important information for pathogenesis and treatment. 
Furthermore, recent studies have suggested that, com-
pared with single SNP approaches for genetic association 
studies, analyses based on haplotypes can significantly 
improve robustness and the power for detecting associa-
tions between markers and disease [1,27]. Ryk et al. [28] re-
ported that some haplotypes of the XRCC1 gene may con-
tribute to genetic susceptibility for non-small cell lung 
cancer. Furthermore, smoking status appears to play an 
important role in the association of the XRCC1 polymor-
phisms and haplotypes with the risk of non-small cell lung 
cancer. Another study showed that the IL1B-1464-C/C 
genotype was associated with increased prevalence of 
atrophic gastritis in the antrum of the stomach and that 
IL1RN*2 individually, or in its haplotype configuration, is 
linked to the presence of premalignant lesions in Cauca-
sians [29]. For CRC, Park et al. [30] reported that the com-
mon haplotype, TIMP2-418*G303*G, was associated with 
an increased risk for CRC compared with the controls, 
while the MMP2-735*C-1575*G common haplotype was 
associated with decreased susceptibility for CRC com-
pared with the controls. Although the haplotype of CTTN 
g.-9101C＞T, g.-8748C＞T, and g.72C＞T did not differ be-
tween CRC and the controls, genetic polymorphisms often 
vary significantly among different groups. Therefore, 
large-scale studies are needed to clarify the associations of 
the single polymorphisms, gene-gene interactions, and 
gene-environment interactions with CRC in well-defined 
groups.
In conclusion, the genotype and allele frequencies of 
CTTN g.-9101C＞T were significantly higher in lymph 
node-positive CRC patients compared to the controls. 
However, the genotype and allele frequencies of g.-8748C＞T 
and g.72C＞T did not differ between the CRC patient 
group and the control group. In addition, the haplotype of 
CTTN g.-9101C＞T, g.-8748C＞T, and g.72C＞T did not 
differ between the CRC patient group and the control 
group. The results showed an association between a spe-
cific CTTN polymorphism and lymph node metastasis of 
CRC. However, further studies with large populations 
and the CTTN g.-9101C＞T, g.-8748C＞T, and g.72C＞T 
polymorphisms are require to elucidate their role in CRC.
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